DOI 10.1007/s00108-025-02033-w
[Staphylococcus aureus bacteremia: the long road to adequate therapy : Recent studies].
Аннотация
BACKGROUND
Staphylococcus aureus bacteremia (SAB) is a heterogeneous and difficult-to-treat disease with a high mortality rate.
OBJECTIVES
Presentation of the challenges of randomized controlled trials (RCTs) on SAB, and an overview of the current state of research and future studies.
METHODS
Search for RCTs on SAB in PubMed and clinicaltrials.gov over the past 20 years.
RESULTS
The design and implementation of RCTs on SAB is complex. Current RCTs incorporate new developments such as pragmatic study design, adaptive platform studies, endpoints with a desirability of outcome ranking (DOOR) and enrichment of clinical phenotypes. The latest results regarding therapy show that cefazolin is not inferior to flucloxacillin in the treatment of methicillin-susceptible S. aureus (MSSA)-SAB and is less nephrotoxic. There is no general recommendation for combination therapy. In low-risk SAB, early oral switch therapy is possible after 5-7 days.
CONCLUSIONS
RCTs on SAB therapy require careful planning and inclusion of subgroups. Further RCTs are necessary to optimize therapy.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.